Institutional Biosafety Committee
IBC Contact Information     IBC Administratior: Daniel Crabtree
Research Compliance Manager: Sheila Anderman IBC Chair: Jakob Waterborg, Ph.D.     Email: WaterborgJ@umkc.edu UMKC BSO (BioSafety Officer): Tim Sturgis     Email: SturgisT@umkc.edu    Phone: (816) 235-1844 BSO for CMH (Children's Mercy Hospital): Yolanda Arriaga    Email: ylarriaga@cmh.edu BSO for Saint Luke's Hospital: Bill Ward    Email: BWard@saint-lukes.org BSO for TMC (Truman Medical Center): Robert Halphin    Email: Robert.halphin@tmcmed.org
Manuals - Essential Information
The UMKC Biosafety Manual (Updated November 2009) is available on-line. NIH Guidelines for Research Involving Recombinant DNA Molecules (2009) In October 2009, these new Guidelines have replaced the older 2002 version of the Guidelines. CDC BMBL-5 Manual (Biosafety in Microbiological and Biomedical Laboratories, 5th Edition) (2007)
IBC Responsibilities UMKC's Institutional Biosafety Committee (IBC) is responsible to regulate the safe acquisition, use and disposal of all biological hazards at the university, including recombinant DNA, infectious agents and toxins. This responsibility is described in the IBC Policy and Procedure Manual, including IBC's Standard Operating Procedures (SOP's) UMKC's IBC is the IBC-of-record for research at affiliated Kansas City institutions (Children's Mercy Hospital, Saint Luke's Hospital and Truman Medical Center). The IBC and its Biosafety Officers (BSOs) are responsible to evaluate and monitor research and teaching at UMKC and the affiliated institutions for biological safety considerations.	Approved IBC Minutes November, 2007 February 2008 May 2008 August 2008 November 2008 February 2009 May 2009 August 2009 November 2009	Scheduled IBC Meetings Quarterly Meetings and as-needed August 18, 2009 at 5211 Rockhill Road, 3 p.m. November 17, 2009 at 5211 Rockhill Road, 3 p.m.
IBC Application     An OnLine application process is under development: (see Menu "IBC Protocols") Complete the IBC Application Form (Word file) In addition, depending on the type of research, complete one or more Appendices (A-1, A-2, A-3, A-4): A-1 Form in case of research or teaching involving Recombinant DNA (Exempt or Non-Exempt) (see NIH Guidelines)       (Updated version, approved 08/18/2009) A-2 Form in case of research or teaching involving Biosafety Level 2 (BLS-2) or 3 (BSL-3) Infectious Agents, Select Agents, and Biological Toxins (see CDC BMBL-5) A-3 Form in case of research requiring Biosafety Level 3 (BSL-3) Containment Measures A-4 Form in case of research or teaching that may lead to exposure of human Bloodborne Pathogens and Other Potentially Infectious Material (OPIM) Approved Protocols provide authorization for three years, with the requirement for annual continuation and for interim amendments in case of changes in research or personnel. Depending on the type of research, approvals by other UMKC compliance committees such as IACUC, IRB or RSC may be required before research can be initiated. If your research involves Human Gene Transfer, please contact the IBC Administrator.